| 22-37 |
Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline LLC, et al. |
Federal Circuit |
2022-07-13 |
Denied |
active-inducement fda-approval generic-drug generic-drugs hatch-waxman-act inducement-doctrine patent-infringement skinny-label |
Whether a generic drug manufacturer can be held liable for inducing infringement of a patent on a use that its FDA-approved label has expressly carved… |
| 21A677 |
Teva Pharmaceuticals USA, Inc. v. GlaxoSmithKline LLC, et al. |
Federal Circuit |
2022-05-03 |
Presumed Complete |
None |
|
| 19-1444 |
GlaxoSmithKline LLC v. United Food and Commercial Workers Local 1776 and Participating Employers Health and Welfare Fund, et al. |
Third Circuit |
2020-07-01 |
Denied |
avandia brand-name-drug brand-name-drugs conflict-preemption drug-labeling drug-manufacturer fda-preemption fda-regulations label-change material-information regulatory-compliance tort-claims |
Whether federal law preempts state-law tort claims where a brand-name drug's manufacturer provides the FDA with all material information in its posses… |
| 18-42 |
GlaxoSmithKline LLC v. Louisiana |
Third Circuit |
2018-07-09 |
Dismissed |
11th-amendment absent-class-member civil-procedure class-action due-process federal-court federal-courts federalism opt-out rule-23 sovereign-immunity state-sovereign-immunity |
Whether state sovereign immunity bars a federal court from binding a State to a Rule 23 class settlement as an absent class member plaintiff based on … |